title: Andexanet: Effectively Reversing Anticoagulation.
abstract: Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.
authors.affiliation: Section of Clinical Biochemistry, University of Verona, Verona, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lippi
authors.affiliation: Research Institute of Hospital 12 de Octubre ("i+12"), Madrid, Spain. Electronic address: fabian.sanchis@uv.es.
authors.forename: Fabian
authors.initials: F
authors.lastname: Sanchis-Gomar
authors.affiliation: Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
authors.forename: Emmanuel J
authors.initials: EJ
authors.lastname: Favaloro
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects*; D000931:Antidotes / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects; D015951:Factor Xa / Q000494:pharmacology*; D006801:Humans; D011994:Recombinant Proteins / Q000494:pharmacology*
chemical_list: D000925:Anticoagulants; D000931:Antidotes; C580915:PRT064445; D011994:Recombinant Proteins; D015951:Factor Xa
keywords: Anticoagulants; andexanet; antidote; apixaban; rivaroxaban